the invention describes the isolation procedure and selection of new strains of lactobacillus and bifidobacterium in the human intestinal mucosa biopti\u010dnih samples. strains were selected on the basis of susceptibility to antimicrobials, viability in simulated gastrointestinal conditions and environment of the antimicrobial activity.the basis for this invention, the entire sequence of lactobacillus fermentum l930bb genomics and bifidobacterium animalis subsp. animalis im386.the invention relates to the use of any of these two strains, or both together in the production of probioti\u010dnega or pharmaceutical product, especially in the prevention and treatment of functional gastrointestinal disorders and \/ or in the lower digestive tract diseases, such as irritable bowel syndrome (ibs) and chronic inflammatory bowel disease (ibd) (crohns disease and ulcerative colitis).Predloženi izum opisuje postopek izolacije in selekcije novih sevov Lactobacillus in Bifidobacterium iz bioptičnih vzorcev človeške črevesne sluznice. Sevi so bili izbrani na osnovi občutljivosti za protimikrobne snovi, sposobnosti preživetja v simuliranih razmerah okolja prebavil in izkazovanja protimikrobne aktivnosti. Osnova za ta izum so tudi celotna genomska zaporedja Lactobacillus fermentum L930BB in Bifidobacterium animalis subsp. animalis IM386. Izum se nanaša na uporabo kateregakoli od teh dveh sevov ali obeh skupaj v proizvodnji probiotičnega ali farmacevtskega izdelka, predvsem pri preprečevanju in/ali zdravljenju funkcionalnih motenj prebavil in bolezni v območju spodnjega prebavnega trakta, kot so sindrom razdražljivega črevesja (IBS) in kronične vnetne črevesne bolezni (IBD) (Crohn-ova bolezen in ulcerozni kolitis).
